دورية أكاديمية
أعرض في EDS

Multiple urinary peptides are associated with hypertension: a link to molecular pathophysiology.

التفاصيل البيبلوغرافية
العنوان: Multiple urinary peptides are associated with hypertension: a link to molecular pathophysiology.
المؤلفون: Mavrogeorgis E; Mosaiques Diagnostics GmbH, Hannover.; Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University Hospital, Aachen, Germany., Kondyli M; University of Patras, Department of Pharmacy, Patras., Mischak H; Mosaiques Diagnostics GmbH, Hannover., Vlahou A; Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece., Siwy J; Mosaiques Diagnostics GmbH, Hannover., Rossing P; Steno Diabetes Center Copenhagen, Herlev.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Campbell A; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Mels CMC; Hypertension in Africa Research Team (HART), Faculty of Health Sciences.; MRC Research Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa., Delles C; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK., Staessen JA; Research Institute Alliance for the Promotion of Preventive Medicine, Mechelen., Latosinska A; Mosaiques Diagnostics GmbH, Hannover., Persu A; Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires Saint-Luc.; Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
المصدر: Journal of hypertension [J Hypertens] 2024 Aug 01; Vol. 42 (8), pp. 1331-1339. Date of Electronic Publication: 2024 Mar 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health, Inc Country of Publication: Netherlands NLM ID: 8306882 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5598 (Electronic) Linking ISSN: 02636352 NLM ISO Abbreviation: J Hypertens Subsets: MEDLINE
أسماء مطبوعة: Publication: [Alphen aan den Rijn, the Netherlands] : Wolters Kluwer Health, Inc.
Original Publication: London ; New York : Gower Academic Pub., [1983-
مواضيع طبية MeSH: Hypertension*/urine , Hypertension*/physiopathology, Humans ; Female ; Male ; Middle Aged ; Peptides/urine ; Blood Pressure ; Biomarkers/urine ; Aged ; Cohort Studies ; Diabetes Mellitus, Type 2/urine ; Diabetes Mellitus, Type 2/physiopathology ; Diabetes Mellitus, Type 2/complications ; Adult
مستخلص: Objectives: Hypertension is a common condition worldwide; however, its underlying mechanisms remain largely unknown. This study aimed to identify urinary peptides associated with hypertension to further explore the relevant molecular pathophysiology.
Methods: Peptidome data from 2876 individuals without end-organ damage were retrieved from the Human Urinary Proteome Database, belonging to general population (discovery) or type 2 diabetic (validation) cohorts. Participants were divided based on systolic blood pressure (SBP) and diastolic BP (DBP) into hypertensive (SBP ≥140 mmHg and/or DBP ≥90 mmHg) and normotensive (SBP <120 mmHg and DBP <80 mmHg, without antihypertensive treatment) groups. Differences in peptide abundance between the two groups were confirmed using an external cohort ( n  = 420) of participants without end-organ damage, matched for age, BMI, eGFR, sex, and the presence of diabetes. Furthermore, the association of the peptides with BP as a continuous variable was investigated. The findings were compared with peptide biomarkers of chronic diseases and bioinformatic analyses were conducted to highlight the underlying molecular mechanisms.
Results: Between hypertensive and normotensive individuals, 96 (mostly COL1A1 and COL3A1) peptides were found to be significantly different in both the discovery (adjusted) and validation (nominal significance) cohorts, with consistent regulation. Of these, 83 were consistently regulated in the matched cohort. A weak, yet significant, association between their abundance and standardized BP was also observed.
Conclusion: Hypertension is associated with an altered urinary peptide profile with evident differential regulation of collagen-derived peptides. Peptides related to vascular calcification and sodium regulation were also affected. Whether these modifications reflect the pathophysiology of hypertension and/or early subclinical organ damage requires further investigation.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: Latosinska A, Siwy J, Mischak H, Frantzi M. Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: the past, the present, and the future. Electrophoresis 2019; 40:2294–2308.
Catanese L, Siwy J, Mischak H, Wendt R, Beige J, Rupprecht H. Recent advances in urinary peptide and proteomic biomarkers in chronic kidney disease: a systematic review. Int J Mol Sci 2023; 24:9156.
He T, Mischak M, Clark AL, Campbell RT, Delles C, Díez J, et al. Urinary peptides in heart failure: a link to molecular pathophysiology. Eur J Heart Fail 2021; 23:1875–1887.
Mavrogeorgis E, He T, Mischak H, Latosinska A, Vlahou A, Schanstra JP, et al. Urinary peptidomic liquid biopsy for noninvasive differential diagnosis of chronic kidney disease. Nephrol Dial Transplant 2024; 39:453–462.
Jaimes Campos MA, Andújar I, Keller F, Mayer G, Rossing P, Staessen JA, et al. Prognosis and personalized in silico prediction of treatment efficacy in cardiovascular and chronic kidney disease: a proof-of-concept study. Pharmaceuticals (Basel) 2023; 16:1298.
Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol 2020; 8:301–312.
Latosinska A, Siwy J, Faguer S, Beige J, Mischak H, Schanstra JP. Value of urine peptides in assessing kidney and cardiovascular disease. Proteomics Clin Apps 2021; 15:2000027.
Wei D, Melgarejo JD, Van Aelst L, Vanassche T, Verhamme P, Janssens S, et al. Prediction of coronary artery disease using urinary proteomics. Eur J Prev Cardiol 2023; 30:1537–1546.
Good DM, Zürbig P, Argilés À, Bauer HW, Behrens G, Coon JJ, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010; 9:2424–2437.
Zhang Z, Staessen JA, Thijs L, Gu Y, Liu Y, Jacobs L, et al. Left ventricular diastolic function in relation to the urinary proteome: A proof-of-concept study in a general population. Int J Cardiol 2014; 176:158–165.
Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, et al. Cohort profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research on health and illness. Int J Epidemiol 2013; 42:689–700.
Lindhardt M, Persson F, Zürbig P, Stalmach A, Mischak H, Zeeuw DD, et al. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrol Dial Transplant 2017; 32:1866–1873.
Lindhardt M, Persson F, Currie G, Pontillo C, Beige J, Delles C, et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open 2016; 6:e010310.
Mischak H, Kolch W, Aivaliotis M, Bouyssié D, Court M, Dihazi H, et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl 2010; 4:464–478.
Mischak H, Vlahou A, Ioannidis JPA. Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem 2013; 46:432–443.
Mavrogeorgis E, Mischak H, Latosinska A, Siwy J, Jankowski V, Jankowski J. Reproducibility evaluation of urinary peptide detection using CE-MS. Molecules 2021; 26:7260.
Jantos-Siwy J, Schiffer E, Brand K, Brand K, Schumann G, Schumann G, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009; 8:268–281.
Staessen JA, Wendt R, Yu Y-L, Kalbitz S, Thijs L, Siwy J, et al. Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study. Lancet Digit Health 2022; 4:e727–e737.
R Core Team. R: a language and environment for statistical computing. 2023. https://www.R-project.org . [Accessed 31 October 2023].
Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al. Welcome to the Tidyverse. J Open Source Softw 2019; 4:1686.
Robinson D, Hayes A, Couch S. broom: convert statistical objects into tidy Tibbles 2023; https://broom.tidymodels.org/https://broom.tidymodels.org/ , https://github.com/tidymodels/broom . [Accessed 09 June 2023].
Firke S. janitor: simple tools for examining and cleaning dirty data 2023; https://github.com/sfirke/janitorhttps://github.com/sfirke/janitor , https://sfirke.github.io/janitor/ . [Accessed 02 February 2023].
Ho D, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011; 42:1–28.
2023; Koncevičius K. matrixTests: fast statistical hypothesis tests on rows and columns of matrices. https://cran.r-project.org/web/packages/matrixTests/index.htmlhttps://cran.r-project.org/web/packages/matrixTests/index.html . [Accessed 05 October 2023].
Hebbali A. olsrr: tools for building OLS regression models. 2020. https://olsrr.rsquaredacademy.com/ , https://github.com/rsquaredacademy/olsrr . [Accessed 10 February 2020].
Harrell FEJ. Hmisc: Harrell miscellaneous. 2023. https://hbiostat.org/R/Hmisc/ . [Accessed 12 September 2023].
von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Foglierini M, et al. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res 2005; 33:D433–437.
Tomaszewski M, Morris AP, Howson JMM, Franceschini N, Eales JM, Xu X, et al. Kidney omics in hypertension: from statistical associations to biological mechanisms and clinical applications. Kidney Int 2022; 102:492–505.
Boder P, Mary S, Mark PB, Leiper J, Dominiczak AF, Padmanabhan S, et al. Mechanistic interactions of uromodulin with the thick ascending limb: perspectives in physiology and hypertension. J Hypertens 2021; 39:1490–1504.
Garimella PS, du Toit C, Le NN, Padmanabhan S. A genomic deep field view of hypertension. Kidney Int 2023; 103:42–52.
De Beer D, Mels CMC, Schutte AE, Delles C, Mary S, Mullen W, et al. Identifying a urinary peptidomics profile for hypertension in young adults: the African-PREDICT study: urinary peptidomics and hypertension: urinary peptidomics and hypertension. Proteomics 2023; 23:e2200444.
Javier BB, Loeys B, Mayr M, Rienks M, Verstraeten A, Kovacic JC. Extracellular matrix in vascular disease, part 2/4. J Am Coll Cardiol 2020; 75:2189–2203.
Manon-Jensen T, Kjeld NG, Karsdal MA. Collagen-mediated hemostasis. J Thromb Haemost 2016; 14:438–448.
del M-NG, Fischer JW, Gorski DJ, Harvey RP, Kovacic JC. Basic biology of extracellular matrix in the cardiovascular system, Part 1/4. J Am Coll Cardiol 2020; 75:2169–2188.
Roumeliotis S, Dounousi E, Eleftheriadis T, Liakopoulos V. Association of the inactive circulating matrix Gla protein with Vitamin K intake, calcification, mortality, and cardiovascular disease: a review. Int J Mol Sci 2019; 20:E628.
Fraser JD, Price PA. Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. Implications for the possible functions of matrix Gla protein and for the tissue distribution of the gamma-carboxylase. J Biol Chem 1988; 263:11033–11036.
El-Maadawy S, Kaartinen MT, Schinke T, Murshed M, Karsenty G, McKee MD. Cartilage formation and calcification in arteries of mice lacking matrix Gla protein. Connect Tissue Res 2003; 44: (Suppl 1): 272–278.
Epstein M. Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. Lancet Diabetes Endocrinol 2015; 3:993–1003.
Chirinos JA, Sardana M, Syed AA, Koppula MR, Varakantam S, Vasim I, et al. Aldosterone, inactive matrix gla-protein, and large artery stiffness in hypertension. J Am Soc Hypertens 2018; 12:681–689.
Malhotra R, Nicholson CJ, Wang D, Bhambhani V, Paniagua S, Slocum C, et al. Matrix Gla protein levels are associated with arterial stiffness and incident heart failure with preserved ejection fraction. Arterioscler Thromb Vasc Biol 2022; 42:E61–E73.
Fain ME, Kapuku GK, Paulson WD, Williams CF, Raed A, Dong Y, et al. Inactive matrix Gla protein, arterial stiffness, and endothelial function in African American hemodialysis patients. Am J Hypertens 2018; 31:735–741.
Wei F-F, Trenson S, Monney P, Yang W-Y, Pruijm M, Zhang Z-Y, et al. Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction. PLoS One 2018; 13:e0193967.
Liu Y-P, Gu Y-M, Thijs L, Knapen MHJ, Salvi E, Citterio L, et al. Inactive matrix Gla protein is causally related to adverse health outcomes: a Mendelian randomization study in a Flemish population. Hypertension 2015; 65:463–470.
Wei F-F, Drummen NEA, Schutte AE, Thijs L, Jacobs L, Petit T, et al. Vitamin K dependent protection of renal function in multiethnic population studies. EBioMedicine 2016; 4:162–169.
Mary S, Boder P, Padmanabhan S, McBride MW, Graham D, Delles C, et al. Role of uromodulin in salt-sensitive hypertension. Hypertension 2022; 79:2419–2429.
Padmanabhan S, Melander O, Johnson T, Blasio AMD, Lee WK, Gentilini D, et al. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLOS Genet 2010; 6:e1001177.
Jaimes Campos MA, Mavrogeorgis E, Latosinska A, Eder S, Buchwinkler L, Mischak H, et al. Urinary peptide analysis to predict the response to blood pressure medication. Nephrol Dial Transplant 2023; gfad223 doi: 10.1093/ndt/gfad223. [Online ahead of print]. (PMID: 10.1093/ndt/gfad223.)
المشرفين على المادة: 0 (Peptides)
0 (Biomarkers)
تواريخ الأحداث: Date Created: 20240501 Date Completed: 20240627 Latest Revision: 20240627
رمز التحديث: 20240627
DOI: 10.1097/HJH.0000000000003726
PMID: 38690919
قاعدة البيانات: MEDLINE
الوصف
تدمد:1473-5598
DOI:10.1097/HJH.0000000000003726